Novartis Sale Of US Oral Generics Unit Seems Unlikely

The Swiss giant's Sandoz division is exploring options for its underperforming US oral generics unit but reports that it may...

      

Related Stories

• AstraZeneca's Imfinzi Scores First Early Lung Cancer Approval
• Pipeline Watch: Phase III Progress With Avelumab, Ixekizumab And Eravacycline
• Celgene's IBD Franchise Boosted by Otezla Ulcerative Colitis Success

 

Original Article: Novartis Sale Of US Oral Generics Unit Seems Unlikely

More From BioPortfolio on "Novartis Sale Of US Oral Generics Unit Seems Unlikely"

• Related Companies
• Related Events
• Related Clinical Trials
• Related PubMed Entries
• Related Medications